Editor: What To Know
- These studies, undertaken at the Halperin Cardiology Bioengineering Laboratory at the Johns Hopkins Hospital, confirmed the Company's foundational concept that multiple CPR pump mechanisms can be combined to produce dramatic improvements in hemodynamics.
- In a widely used model of cardiac arrest, the Company's multimodal CPR resulted in more than 50% improvements in indicators of vital organ perfusion.
- Paradis is an emergency medicine physician and Professor at the Geisel School of Medicine at Dartmouth.
Today CPR Therapeutics Inc. announced they have completed early-phase proof-of-principal studies of its integrated cardiopulmonary resuscitation (CPR) system. These studies, undertaken at the Halperin Cardiology Bioengineering Laboratory at the Johns Hopkins Hospital, confirmed the Company’s foundational concept that multiple CPR pump mechanisms can be combined to produce dramatic improvements in hemodynamics.
Norman Paradis MD, the Company’s Founder and CEO stated: “We are pleased that these early studies provided such a strong signal of efficacy. Hemodynamic improvements of this magnitude are unheard of in resuscitation research. They strongly indicate that we’re on the right track and that our human prototype system will have a positive clinical trial.” Dr. Paradis is an emergency medicine physician and Professor at the Geisel School of Medicine at Dartmouth.
Dr. Henry Halperin, the Company’s Chief Scientific Officer: “This is very exciting. While the hypothesis that multiple CPR pump mechanisms might be synergistically combined had face-validity, it is good to see actual data.” Dr. Halperin is a cardiologist and the David J. Carver Professor of Medicine at Johns Hopkins University.
In a widely used model of cardiac arrest, the Company’s multimodal CPR resulted in more than 50% improvements in indicators of vital organ perfusion.
Dr. Paradis added “improvements like this are predictive of significantly increased rates of successful resuscitation. We look forward to continuing with our prototype R&D and moving toward clinical trials.”
